CLINICAL USE

Anti-emetic:For use with cancer chemotherapy

DOSE IN NORMAL RENAL FUNCTION

250 mcg as a single dose approximately 30 minutes before chemotherapy

PHARMACOKINETICS

  • Molecular weight                           :332.9 (as hydrochloride)
  • %Protein binding                           :62
  • %Excreted unchanged in urine     : 40
  • Volume of distribution (L/kg)       :6.9–7.9
  • half-life – normal/ESRD (hrs)      :40

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Unlikely to be dialysed. Dose as in normal renal function
  • HD                     :Unlikely to be dialysed. Dose as in normal renal function
  • HDF/high flux   :Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD      :Unlikely to be dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsNone

    ADMINISTRATION

    Reconstition

    –

    Route

    IV bolus

    Rate of Administration

    30 seconds

    Comments

    –

    OTHER INFORMATION

    Repeated doses within 7 days are not recommendedUse with caution in people at risk of QT prolongation.

    • Tags:

    Related News

    ffddfd

    Hyperlipidemia